Identifying the peptidases that inactivate bioactive peptides (e.g., peptide hormones and neuropeptides) in mammals is an important unmet challenge. this protocol describes a recent approach that uses liquid chromatography-mass spectrometry (lc-Ms) peptidomics to identify endogenous cleavage sites of a bioactive peptide; it also addresses the subsequent biochemical purification of a candidate peptidase on the basis of these cleavage sites and the validation of the candidate peptidase's role in the physiological regulation of the bioactive peptide by examining a peptidase-knockout mouse. We highlight the successful application of this protocol in the discovery that insulin-degrading enzyme (IDe) regulates physiological calcitonin gene-related peptide (cGrp) levels, and we detail the key stages and steps in this approach. this protocol requires 7 d of work; however, the total time for this protocol is highly variable because of its dependence on the availability of biological reagents such as purified enzymes and knockout mice. the protocol is valuable because it expedites the characterization of mammalian peptidases, such as IDe, which in certain instances can be used to develop novel therapeutics. not rely on any in vivo information about the regulation of the bioactive peptide, it is prone to causing mistakes. As the effort it takes to validate the regulation of a bioactive peptide through selective inhibitors and/or knockout mice is so great, a high failure rate is unacceptable. Thus, this vasopressin example and others highlight the need for a more effective protocol for the discovery of the peptidases that regulate bioactive peptides.
IntroDuctIon
Human bioactive peptides, such as insulin 1 and glucagon 2, 3 , have a rich scientific history and represent a class of important medicines 4 . Before the advent of molecular biology techniques 5, 6 , such molecules were isolated and identified by biochemical purification guided by activity assays [7] [8] [9] . Testing for compounds that reduced glucose levels in dogs, for example, led to the isolation of insulin 1 . Although biochemical purification is a powerful strategy for identifying bioactive peptides, this approach reveals nothing about the regulation, biosynthesis, catabolism and/or post-translational regulation of these molecules [10] [11] [12] . Although insulin can be used acutely to treat diabetes through injections when blood glucose levels are elevated, the amounts of other bioactive peptides must be perturbed for much longer periods to achieve therapeutic value 13, 14 . Unfortunately, the instability of peptides in vivo, where they are susceptible to inactivation by proteolytic cleavage 15 , makes this a challenging task.
Targeting the biochemical pathways that regulate the production and degradation of bioactive peptides can also control endogenous peptide levels. Most bioactive peptides are synthesized as longer pre-proproteins and then undergo proteolysis by a class of proteases called prohormone convertases (PCs) to produce the mature bioactive peptides 16, 17 . Disruption of the proteases in these pathways leads to deficiencies in peptide production, but these pathways cannot be used to regulate the levels of individual peptides because PCs are responsible for the production of multiple bioactive peptides. The deletion of the gene encoding prohormone convertase 2 (PC2) in mice, for example, results in higher proinsulin levels and lower insulin levels, but these animals do not show a diabetic phenotype because PC2-encoding gene deletion also results in the loss of glucagon 11, 18, 19 .
Peptidases have also been found to regulate the activity of some bioactive peptides after their release from cells, and targeting these enzymes has enabled controlling the amounts of specific bioactive peptides. A classic example is the proteolysis of angiotensin I to produce angiotensin II, a potent vasoconstrictor 14 , by the angiotensin-converting enzyme (ACE). Small-molecule ACE inhibitors have been used in the clinic for many years, and they lower the blood pressure by reducing angiotensin II levels. More recently, small-molecule inhibitors of renin, the protease responsible for the production of angiotensin I, have been developed, and these compounds have successfully been used to reduce blood pressure because they also lead to lower angiotensin II levels 20 .
This strategy has also found success in the treatment of metabolic disease. Glucagon-like peptide 1 (GLP-1), an intestinal peptide produced from the gene encoding glucagon, promotes glucose-stimulated insulin secretion (GSIS) from pancreatic islets 21 . Administration of GLP-1 in mammals results in elevated insulin levels and reduced blood glucose levels 22 , suggesting that this peptide may be a valuable therapeutic. Unfortunately, GLP-1 has a short half-life because of proteolysis 12, 23 , which prevents it from being an effective drug. Consequently, the focus shifted toward the identification of the enzyme(s) responsible for GLP-1 proteolysis, which revealed that dipeptidyl peptidase 4 (DPP4) is responsible for GLP-1 inactivation 24 . This insight resulted in the development of small-molecule DPP4 inhibitors as antidiabetic drugs. The ACE and DPP4 examples highlight the value of identifying peptidases that regulate bioactive peptides in characterizing the role of these enzymes in vivo 14 and providing new opportunities in therapeutic development 25, 26 .
Moreover, these examples suggest that the partial proteolysis of bioactive peptides is a common form of biochemical regulation in mammals. Although there are many known bioactive peptides, we know relatively little about the physiological proteolysis of these molecules. This dearth of knowledge is primarily due to the lack of an effective protocol for elucidating the enzymes that regulate bioactive peptides. The typical approach tries to connect peptidases to particular bioactive peptides on the basis of their substrate specificity. For example, the neuropeptide vasopressin is a terrific substrate for the enzyme prolyl endopeptidase in vitro 27 , suggesting that vasopressin may be regulated by prolyl endopeptidase. However, inhibition of prolyl peptidase does not change vasopressin levels in the nervous system. Because this approach does not rely on any in vivo information about the regulation of the bioactive peptide, it is prone to causing mistakes. As the effort it takes to validate the regulation of a bioactive peptide through selective inhibitors and/or knockout mice is so great, a high failure rate is unacceptable. Thus, this vasopressin example and others highlight the need for a more effective protocol for the discovery of the peptidases that regulate bioactive peptides.
There are three key stages in our protocol for identifying peptidases that cleave and inactivate bioactive peptides (Fig. 1) . The first is the use of MS peptidomics to identify endogenous fragments of bioactive peptides to reveal the natural cleavage sites (i.e., the proteolytic pathway). The second stage is the development of a peptidase-isolation assay using tissue lysates to isolate the candidate peptidase(s) that are able to produce these fragments. The final step is the physiological validation of proteolysis to ensure that the pathway and enzyme actually regulate the endogenous peptide. This is accomplished by inhibition of the enzyme and quantitative measurements of the endogenous peptide levels. Notably, this approach overcomes the challenges with current methods, because it uses knowledge of endogenous peptide fragments to drive discovery, which removes any doubt about the relevance of particular cleavage sites.
Experimental design
In developing this protocol, we wanted to answer the following two questions concerning bioactive peptide proteolysis: can we identify the endogenous cleavage sites for a given bioactive peptide? Can we use this information to quickly identify and validate the peptidase(s) responsible for endogenous bioactive peptide proteolysis? We highlight our work with two bioactive peptides: peptide histidine isoleucine (PHI) [28] [29] [30] and CGRP [31] [32] [33] [34] [35] [36] [37] [38] . We selected these peptides because of their interesting biological activities and because of the lack of knowledge about their proteolytic regulation. In theory, a peptidase that cleaves any bioactive peptide can be identified using this protocol.
In stage 1 of this protocol ( Fig. 1) , we use LC-MS peptidomics to identify all the fragments of a given bioactive peptide, such as PHI or CGRP, in tissues in which they are found. In the case of CGRP, for example, we isolated mouse spinal cord peptides smaller than 10 kDa using molecular-weight-cutoff (MWCO) filters and analyzed these peptides by MS using a standard setup for shotgun LC-MS proteomics 39 . Peptidomics experiments are distinguished from proteomics experiments in that they include this MWCO step, and in this case they also lack a trypsin digestion step, as we are trying to identify cleavage sites. As the detection of low-abundance peptides can be stochastic, different peptide fragments can occasionally be identified in different runs. To reduce the possibility that a peptide is missed, we recommend performing at least three replicates (biological or technical replicates) and using the data from all three experiments.
After LC-MS, the data are analyzed with SEQUEST 40 , a tandem MS peptide-identification program. With SEQUEST, peptides that are detected in a sample are grouped by the gene or protein from which they derive, and thus any CGRP fragments can easily be identified 41 . Although we have not used other peptide identification programs such as MASCOT 42 or MaxQuant 43 , these programs provide similar information to SEQUEST and can be substituted. We recommend using stringent scoring criteria for the spectra and visually inspecting spectra to improve confidence in the fragment identification. As all subsequent steps depend on this data set, this additional validation step is worth the modest time it adds to the analysis.
There have been several attempts to identify CGRP's cleavage sites using immunoassays 41 . In these experiments, tissue samples were fractionated using gel chromatography (Sephadex G50), and individual fractions were tested for CGRP immunoreactivity using an antibody specific to the C-terminal epitope of CGRP. This analysis identified two predominant fragments, CGRP [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] and CGRP [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] , and the cleavage site was predicted to be between amino acids 18 and 19, because CGRP 19-37 is more abundant. By contrast, peptidomics revealed ten CGRP fragments, including novel fragments and previously identified fragments, which provided further confidence in the data set. Most notably, the unbiased nature of the method allowed identification of two N-terminal peptides, CGRP [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] and CGRP , which revealed that CGRP actually contains two cleavage sites: between amino acids 17 and 18 and amino acids 26 and 27. These peptides could not be detected using the published immunoassay because of the C-terminal specificity of the antibody, which demonstrates the advantages of peptidomics over immunoassays for the identification of endogenous cleavage sites.
CGRP is a widely used marker for staining different parts of the spinal cord, and it is known to be quite abundant 44 . Consequently, its fragments are also likely to be abundant, making them easier to detect. However, if the peptide under investigation is of low abundance, then fragments of this peptide may not be detected by shotgun LC-MS, which is generally biased toward more-abundant peptides [45] [46] [47] [48] . To overcome this issue, different types of LC-MS experiments that target peptide fragments in vivo can be performed to improve the sensitivity of the detection. However, to carry out these experiments, the structures of candidate peptide fragments must be known ahead of time. Therefore, we also recommend performing in vitro assays on lysates to identify candidate peptides, which can then be targeted by LC-MS for more sensitive detection. These in vitro assays are also useful in that they provide more confidence in the endogenous results (Fig. 1) . For example, in our investigation of PHI proteolysis, we incubated synthetic PHI with tissue lysate and identified the fragments generated by matrix-assisted laser desorption/ionization (MALDI) (Fig. 2) 49 . As the concentration of the synthetic peptide added in this experiment is high (10-100 µM) relative to endogenous peptides (lysate is added at 1mg ml − 1 ), only the synthetic peptide will be detected by MALDI, allowing the use of unlabeled peptide for this experiment (Fig. 2a) . After incubating the peptide for 15-60 min with the lysate, a few microliters of the mixture is desalted using a ZipTip and then analyzed by MALDI to identify candidate peptide fragments to look for in tissue lysate experiments. In the case of PHI, incubation of the full-length peptide with intestinal lysate resulted in the production of PHI and PHI 1-21 fragments (Fig. 2) . In addition to analyzing this sample by MALDI, we also performed an LC-MS shotgun proteomics experiment to obtain information about the retention time, mass-to-charge ratios and tandem mass spectra of the relevant PHI fragments (Fig. 2) .
This information about the properties of the different candidate peptide fragments can be used to design a number of different experiments to improve the sensitivity of detection of endogenous peptides. In one approach, the known retention times and mass-to-charge ratios of peptide fragments are used to improve the search for shotgun proteomics data to identify peptides that were present but that were unidentified by SEQUEST. In addition, as tandem MS uses data-dependent acquisition, it is possible that certain peptides are missed because they are not selected for subsequent tandem MS. Knowing the mass-tocharge ratios and retention time of a given bioactive peptide fragment can be used to target peptides for tandem MS, providing a modified experimental workflow for identifying the peptide. By using this targeted approach, for example, we were able to detect PHI 1-21 , but not PHI in vivo, indicating that PHI is not an endogenous PHI fragment in the gut (Fig. 3) 49 . Finally, the same information can also be used to design a targeted multiple reaction monitoring (MRM) LC-MS experiment for each candidate fragment 50 . MRM experiments require a triple quadrupole (QQQ) mass spectrometer, and they provide superior sensitivity for molecules in complex mixtures 50 . Although no approach can guarantee that a fragment will not be missed, performing lysate experiments and targeting those peptides when you are analyzing samples from in vivo experiment using targeted MS can effectively maximize sensitivity and reduce the possibility that a bioactive peptide fragment is missed.
Once the endogenous fragments of a peptide have been identified in stage 1, this information is then used to develop a biochemical model to determine the endogenous cleavage sites (Fig. 1) . For example, the identification of CGRP [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] , CGRP 18-37 , CGRP and CGRP [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] indicated that CGRP is cleaved between amino acids 17 and 18 and amino acids 26 and 27. Thus, in stage 2, we sought to identify candidate enzyme(s) that were able to cleave CGRP at these endogenous cleavage sites (Fig. 1) . For CGRP, we decided to purify candidate enzymes directly from mouse spinal cords to ensure that we identify the candidate peptidase directly from the tissue source.
To be able to isolate the CGRP-degrading enzyme, we needed to be able to follow its activity through various purification steps. We noted that addition of CGRP to spinal cord lysates produced CGRP [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] and CGRP [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] , which were easily detectable by MALDI (Fig. 4) . The CGRP and CGRP 27-37 fragments were also produced in this assay but were less prominent in MALDI spectra, although they were readily detected by LC-MS. With this MALDI assay, we could simply incubate proteome fractions from the fractionation procedure with synthetic CGRP and follow, by MALDI, which fractions retained CGRP-degrading activity. If desired, different peptide substrate assays could be developed at this stage (e.g., a FRET-based peptide analog for measuring cleavage) depending on the type of equipment readily available.
To isolate candidate CGRP-degrading enzymes, we began by fractionating the proteome into soluble and membrane fractions using a simple centrifugation protocol. We then solubilized the membrane fraction. By using the same concentration of total protein from either the membrane or soluble fraction, we then assessed their relative activities by incubating CGRP with each lysate and measuring the production of the key CGRP fragments identified in stage 1, CGRP [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] and CGRP [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] , by MALDI and LC-MS. The relevant CGRP fragments were only produced in the soluble fraction, which allowed us to focus on the soluble proteome when searching for candidate CGRP-degrading enzymes. Next, we used a series of peptidase class-selective small-molecule inhibitors to determine what class of peptidase (metallo, serine, cysteine or aspartyl) is responsible for the CGRP-cleaving activity 41, 49 ( Fig. 4) . Each inhibitor was preincubated with the soluble fraction of spinal cord lysates; this was followed by the addition of CGRP. The degradation of CGRP was then monitored by the amount of CGRP 18-37 generated, as measured by LC-MS. In this case, we found that the metallopeptidase inhibitor (1,10-phenanthroline and EDTA) strongly inhibited CGRP cleavage, indicating that the CGRP-degrading enzyme is a metalloprotease (Fig. 4) . This information on peptidase class was highly useful because it allowed us to focus on candidate metallopeptidases.
To further narrow down candidate CGRP-degrading enzymes, we then proceeded to fractionate the soluble spinal cord proteome, which contained all of the CGRP-degrading activity, by fast protein liquid chromatography (FPLC) (Fig. 4) . Specifically, we used an anion exchange column to separate the proteome into multiple fractions, and then tested each of these fractions for their CGRP-degrading activity. We proceeded to identify the candidate enzymes by analyzing active fractions by proteomics. This proteomics analysis identified three metallopeptidases present in the active fraction, namely IDE 51 , thimet oligopeptidase (THOP) 52 and neurolysin (NLN) 52 , which were thereafter considered candidate CGRP-degrading enzymes (Fig. 4) .
Depending on the peptidase and its location (i.e., soluble versus membrane), the fractionation step has to be optimized on a case-by-case basis. For example, a soluble peptidase, such as the CGRP-degrading enzyme, is easier to work with than a membrane protein, which requires a solubilization step before purification 53 . For membrane peptidases, we recommend solubilizing the membrane fraction using Triton X-100 or another similar surfactant 53 . After solubilizing the membrane, the activity of the enzyme must be checked with the activity assay, such as the CGRP proteolysis assay. If the activity of the enzyme is retained after solubilization of the membrane fraction, then the purification of a membrane protein can proceed in a manner similar to that of a soluble protein, but every individual case will vary.
In the case of the candidate CGRP-degrading enzymes, a single FPLC purification yielded active fractions with only three candidate enzymes, which could easily be tested individually. In some cases, however, many more peptidases could be identified in the active fractions, which would require further optimization and possibly further fractionations. In particular, if a large number ( > 8-10) of candidate peptidases are associated with the active fractions, it may be beneficial to perform a second, orthogonal, fractionation step. This additional fractionation step could be size-exclusion chromatography (SEC) 54 , strong cation exchange (SCX) chromatography 55, 56 or hydrophobic interaction chromatography 57 . All of these would further fractionate the proteome so that the active fractions contain a smaller number of candidate peptidases to validate in subsequent steps.
After identifying IDE, THOP and NLN as metallopeptidases present in the active CGRP-degrading fraction, it was necessary to test each of these peptidases for their ability to cleave full-length CGRP to generate CGRP [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] , CGRP 18-37 , CGRP and CGRP [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] (Figs. 1 and 4) . These proteins are currently all commercially available, but at the time of our work THOP and NLN could not be purchased, and thus they were instead produced by bacterial overexpression according to published procedures for their expression and purification 41 . To ensure that the expressed enzymes were active, we tested each against a known substrate and assessed cleavage. If they are commercially available, we highly recommend purchasing candidate proteins, although they are expensive, because it is fast and ultimately more cost effective when researcher time and reagent cost is taken into account. Each candidate peptidase is then incubated with the fulllength peptide, in this case CGRP, and the proteolysis of this peptide is monitored by LC-MS. THOP and NLN did not cleave CGRP, whereas IDE readily cleaved CGRP to afford the endogenous fragments CGRP [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] , CGRP 18-37 , CGRP and CGRP [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] ( Fig. 4) . Thus, IDE was the only candidate CGRP-degrading enzyme capable of cleaving this peptide at the physiologically relevant sites, and we therefore proceeded to take it to the next stage of the protocol: stage 3, validation in vivo (Fig. 1) .
As a potential alternative to extensive fractionation, databases can also be used to produce a list of candidate enzymes capable of cleaving at a given site in a peptide of interest. The MEROPS database 58, 59 contains information on all proteases and peptidases from a variety of different organisms and offers the opportunity to search this database in a number of different ways, including a search based on enzymes that are predicted to be able to cleave a particular bond. For instance, by using the cleavage sites Ser17-Arg18 and Asn26-Phe27 in CGRP, we obtained lists of candidate peptidases capable of cleaving at each bond. The results from the Ser17-Arg18 search included five metallopeptidases: THOP, IDE, matrix metalloprotease (MMP) 19, meprin and nardilysin. The peptidases from the Asn26-Phe27 search included THOP, NLN, MMP1, MMP2, MMP3, MMP8, MMP9, MMP13, MMP20, ADAMTS4 and ADAMTS1. Of these candidate enzymes, only THOP, IDE, NLN and nardilysin are soluble, and therefore they are likely to be responsible for the CGRP-degrading activity. All of these enzymes are commercially available, which would make testing them for CGRP-cleaving activity straightforward. We recommend using the MEROPS database to identify candidate peptidases because of the speed and relative inexpensiveness of this approach relative to enzyme purification from lysates. A caveat to relying solely on databases, however, is that that they may not be comprehensive and may miss some enzymes. For example, IDE is not listed as one of the enzymes capable of cleaving CGRP between amino acids 26 and 27, but it does so readily. Given that many peptidases and proteases are in fact well characterized, however, this database can be a very valuable tool for predicting candidate peptidases.
Having identified IDE as a candidate CGRP-degrading enzyme capable of cleaving this peptide at the physiologically relevant sites in vitro in stage 2 of this protocol, we then set out to validate IDE as an endogenous CGRP-degrading enzyme in stage 3 ( Fig. 1) .
To do this, we needed to perturb the activity of this enzyme in vivo and quantitatively measure changes in CGRP levels. Ide heterozygote mice (Ide −/+ ) were commercially available, and we bred these animals using standard animal husbandry techniques to isolate the Ide knockout (Ide −/− ) mice that we used in our experiments 60 . If an in vivo model is unavailable, the decision must be made either to create a knockout mouse or to identify alternative methods for testing the connection between an enzyme and a substrate. We believed that IDE was cleaving CGRP extracellularly, and this required us to use an in vivo model; however, if the enzyme-substrate interaction is believed to take place in the cytosol, or if the peptidase and peptide are both secreted, a cell culture model should suffice. It is also possible to use other more genetically tractable organisms, such as Caenorhabditis elegans or Drosophila melanogaster, if they are available and applicable.
The fastest option, if available, is to use a selective smallmolecule inhibitor of the peptidase 25 . Such inhibitors would enable much faster testing of the hypothesis, because wild-type mice can be purchased and tested in a very short time compared with the breeding necessary to get sufficient numbers of knockout mice, especially when homozygous knockouts are not commercially available. In addition, knockout animals sometimes suffer from the emergence of compensatory mechanisms that could mask the role of an enzyme in the regulation of a bioactive peptide. For example, the loss of a peptidase may result in the upregulation of another peptidase to compensate for the knocked-out enzyme 61, 62 . The use of a small-molecule inhibitor overcomes these challenges, because it can acutely inhibit the enzyme, allowing measurements to be made before the onset of any compensation 63 . Therefore, we highly recommend the use of small-molecule peptidase inhibitors when available. These compounds are currently not available for IDE, which prompted our use of knockout mice.
During initial experiments to measure changes in CGRP levels in Ide −/− mice, we noticed a great deal of variability in our data from the ELISA we were using. We suspected that this may have been due to variability in the peptide isolation, and this led us to use a reported protocol termed RAPID (for reduced temperatures, acidification, protease inhibition, isotopic exogenous controls and dilution) 64 that limits proteolysis of peptide hormones for immunoassays (Fig. 5) . The data were better but not good enough, and thus we surmised that the issue was the immunoassay. Although the data always trended toward higher levels of CGRP in Ide −/− mice, the precision of the measurement was not good enough. Therefore, we decided to develop an isotope dilution mass spectrometry (IDMS) assay 41 to reliably and accurately quantify endogenous CGRP levels. When a good immunoassay is commercially available, we do recommend using it to save time.
In an IDMS assay, an isotopically labeled standard, in this case deuterated CGRP (d18-CGRP), is added at a known concentration to the mouse tissue or plasma before peptide extraction. After LC-MS, the endogenous molecule and the labeled standard can be distinguished in the mass spectrometer because of the difference in their molecular weights. The ratio of the peak intensities for the two molecules (endogenous peptide and standard) enables the concentration of the endogenous peptide to be calculated (Fig. 6) . This assay provided a much more reproducible measurement of endogenous CGRP levels and demonstrated that IDE is in fact regulating endogenous CGRP levels (Fig. 6) . This protocol successfully identified the peptidase that regulates CGRP in mammals (Fig. 6) , and it should be applicable to other important peptides moving forward. Amastatin (Sigma-Aldrich, cat. no. A1276)  crItIcal A stock solution of amastatin in methanol is stable for at least 1 month at −20 °C. Synthetic peptides should be purchased when available, and isotopically labeled peptides can either be purchased from a custom synthesis company or prepared by solid-phase peptide synthesis (SPPS) using standard approaches 65 Recombinant peptidases should be purchased (http://www.origene.com) for these assays or expressed and purified using standard techniques in molecular biology and biochemistry 39 SEQUEST SEQUEST is a tandem MS data analysis program used for peptide identification 40 . Peptides are accepted within 1 Da of the expected mass, meeting a series of custom filters on ScoreFinal (Sf), −10 log P and a charge state that attained an average peptide false discovery rate of <2% across data sets. SCX chromatography SCX chromatography is performed using a PolySULFOETHYL A column (200 × 2.1 mm, 5 µm, 300 Å; PolyLC) connected to an Agilent Technologies 1200 series LC. All runs are operated at 0. The proteome is denatured in this step, and doing so inactivates any proteolytic activity before homogenization.  crItIcal step Frozen tissues should be weighed before addition to the ice-cold water in order to enable absolute quantification.
2|
After boiling, separate the aqueous fraction and keep it on ice or in a cold room.
3| Dounce-homogenize the heat-denatured tissues in ice-cold aqueous acetic acid (0.25% vol/vol). We perform at least 10-15 strokes with the each of the A (loose) and B (tight) Douncers to ensure that the sample is completely homogenized.  crItIcal step Use the same number of strokes with the A (loose) and B (tight) Douncer for more consistent results.
4| Combine the aqueous fraction from
Step 2 and the homogenate from Step 3 and centrifuge the mixture at 20,000g for 20 min at 4 °C.
5|
Separate the supernatant from the insoluble pellet and pass it through a 10-kDa-MWCO filter.
6|
Apply the filtrate (i.e., <10-kDa fraction) into a C18 Sep-Pak cartridge and wash it with water (10 ml).
7|
Elute the peptides from the C18 Sep-Pak with 1 ml of 70:30 H 2 O/ACN (vol/vol). This sample is then concentrated under vacuum using a SpeedVac.
8| Dissolve the sample with water, and then fractionate it with SCX chromatography (see Equipment Setup). We use a step gradient of four different salt concentrations (A, B, C and D). After SCX, each of these fractions is desalted using a C18 Sep-Pak cartridge. Each sample (n = 4) is washed with water (25 ml) to remove salts, and then the peptides are eluted from the C18 Sep-Pak with 1 ml of 70:30 H 2 O/acetonitrile and concentrated under vacuum using a SpeedVac.
9|
Dissolve each of these samples in 0.1% (vol/vol) aqueous formic acid before LC-MS/MS analysis. The amount of formic acid solution used to dissolve the sample is calculated using the weight of the tissue used to generate the sample (40 µl of formic acid solution per 75 mg of tissue).  pause poInt These samples can be used right away or they can be stored at −80 °C. We typically use the samples within 1-2 weeks, but they should be stable for much longer periods of time. 
11|
Collect data in full MS mode (n = 4, i.e., no tandem MS spectra) for peptide quantification by using the area under the peak. By not switching between full MS and tandem MS, the LC-MS chromatograms are much smoother, which affords better quantification. To identify the peptides, we then perform a top-six MS 2 experiment, in which the largest six ions during a full MS scan are then subjected to tandem MS, which generates tandem MS spectra that are used to identify the peptide sequences. Importantly, when peptides are not quantified, we simply rely on a top-six experiment to identify these fragments.
12|
Set the dynamic exclusion for these experiments to 30 s for the top-six analysis and set the exclusion size list to 200. Set the capillary spray voltage at 2.5 kV and the normalized collision energy for CID to 35%.
13|
Identify peptide sequences using SEQUEST with differential modification of methionine to its sulfoxide, as described in Equipment Setup.
preparation of tissue lysates • tIMInG 3 h 14| Thaw the frozen tissues on ice (these can be isolated or purchased from various tissue banks).
15| Dounce-homogenize the mouse tissue in 1× PBS (100 µl per 100 mg tissue). We perform at least 10-15 strokes with each of the A (loose) and B (tight) Douncers to ensure that the sample is completely homogenized.
16|
Centrifuge the homogenate at 1,000g at 4 °C for 5 min to remove large cellular debris.
17|
Transfer the supernatant from this spin to a thick-walled centrifuge tube and then centrifuge it at 100,000g at 4 °C for 45 min using a tabletop ultracentrifuge. This separates the sample into the soluble (supernatant) and membrane (pellet) proteomes.
18| Transfer the resulting supernatant to a new Eppendorf tube and use it as the soluble fraction.  crItIcal step Be careful not to contaminate the soluble fraction with the membrane fraction while transferring it.
19|
Wash the pellet twice with 1× PBS, and then suspend it in 100 µl of 1× PBS. This is then used as the membrane fraction.  pause poInt Aliquot the samples (10 µl) and store them at −80 °C until further use.
20|
Determine the protein concentrations of these lysates using the Bradford assay.
21| Dilute all lysates using 1× PBS to a final concentration of 1 mg ml − 1 for subsequent activity assays.
Bioactive peptide proteolysis in tissue lysates • tIMInG 2 h 22| Incubate synthetic peptides (20 µl, 100 µM final concentration) with soluble and membrane lysates (1 mg ml − 1 ) at 37 °C for 15 min.  crItIcal step The reaction time varies for each peptide (5-60 min) and must be optimized to ensure the optimal amount of degradation, as too little or too much proteolysis is not informative. 
29|
Identify peptide sequences using SEQUEST with differential modification of methionine to its sulfoxide, as described in Equipment Setup. If other types of modifications are being studied (i.e., phosphorylation, acetylation, etc.), the search will need to be adapted at this step to enable the detection of differentially modified peptides.
30|
Integrate the area under the curve for specific peptides in the LC-MS chromatogram in order to obtain relative quantitative data for the different peptide fragments generated during the incubation of the full-length peptide with lysates.  crItIcal step To ensure that the quantification is accurate, make sure to account for all charge states for a given peptide fragment.
protease inhibitor assays • tIMInG 6 h 31| Incubate tissue lysates or plasma (1 mg ml −1 ) at 37 °C for 30 min with each protease inhibitor described in Reagent Setup before the addition of the synthetic peptide. Note that if other types of modifications are being studied, the choice of inhibitor can vary. For example, if the PTM of interest is a phosphorylation site, then different kinase inhibitors can be used at this point.
0.1 M ammonium acetate, 0.5 M NaCl and enzyme inhibitors (1 µg ml − 1 of LAF-237, E-64, antipain, leupeptin, chymostatin, 1,10-phenanthroline, N-ethylmaleimide), and then immediately centrifuge the mixture at 3,000g for 10 min at 4 °C.
43|
Transfer the supernatant into a new tube and freeze it at − 80 °C for 24-72 h. After centrifugation, the supernatant is clear and very light pink in color.
44| Precondition a C18 Sep-Pak cartridge by washing it with acetonitrile (3 × 6 ml), followed by washing it with 0.1% (vol/vol) TFA in water (4 × 6 ml) using an extraction manifold.
45|
Thaw the frozen samples on ice and apply 2 ml of each sample onto its own preconditioned C18 Sep-Pak cartridge.  crItIcal step The flow-through from the column is then added back to the column three times to ensure that all of the material is bound to the column.
46|
Wash the Sep-Pak with 0.1% TFA in water (24 ml) and elute it with a 70:30 mixture of acetonitrile/water containing 0.1% (vol/vol) TFA (2 ml total) into protein LoBind tubes.  crItIcal step Allow the acetonitrile/water solution to flow through the Sep-Pak by gravity. After a few minutes, apply pressure using a piston to flush out the remaining solution.
47| Dry the sample using a SpeedVac vacuum concentrator at 25 °C.
48|
Dissolve the sample in water with 0.1% (vol/vol) formic acid (100 µl), centrifuge it at 13,000g (10 min, 4 °C) and desalt 20 µl of this sample using a ZipTip as outlined in Box 1.
? trouBlesHootInG Troubleshooting advice can be found in table 1.
• tIMInG Steps 1-9, isolation of physiological peptides from tissue for peptidomics analysis: 
antIcIpateD results
This protocol details the approach that we have used to study the proteolysis of bioactive peptides. The identification of these pathways promises to elucidate the functions of peptidases in mammals and, in certain cases, to provide new opportunities for therapeutic intervention. This protocol can be applied to any peptide, and the results can be demonstrated for PHI and CGRP (Figs. 2-6 ). Stages 1 and 2 of this process should yield endogenous cleavage sites and candidate peptides, 
